JPMorgan Chase & Co. Reports 4.9% Ownership in Karyopharm Therapeutics Inc.

JPMorgan Chase & Co has filed an amendment to its Schedule 13G, disclosing an increased ownership of 4.9% in Karyopharm Therapeutics Inc. The filing, dated October 17, 2025, reveals that JPMorgan Chase & Co now holds 427,624 shares of Karyopharm's common stock, representing a 66.75% increase in shares and a 129.43% increase in value compared to previous holdings. The shares are held in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing also identifies J.P. Morgan Securities PLC and J.P. Morgan Securities LLC as subsidiaries involved in the ownership. The amendment is filed under Rule 13d-1(b).